Sensorion SA (ALSEN.PA)
EUR 0.64
(-6.16%)
EUR 0.64
(-6.16%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.24 Million EUR | -35.93% |
| 2022 | 1.93 Million EUR | -26.51% |
| 2021 | 2.63 Million EUR | -12.31% |
| 2020 | 3 Million EUR | 339.36% |
| 2019 | 684.08 Thousand EUR | 0.0% |
| 2018 | - EUR | -100.0% |
| 2017 | 1.84 Million EUR | 85.23% |
| 2016 | 998.52 Thousand EUR | 35.21% |
| 2015 | 738.52 Thousand EUR | 22.59% |
| 2014 | 602.45 Thousand EUR | 0.0% |
| 2013 | - EUR | 0.0% |
| 2012 | - EUR | 0.0% |
| 2011 | - EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 890 Thousand EUR | 0.0% |
| 2023 Q4 | 1.24 Million EUR | 0.0% |
| 2023 Q2 | 1.58 Million EUR | 0.0% |
| 2023 FY | 1.24 Million EUR | -35.93% |
| 2022 Q4 | 1.93 Million EUR | 0.0% |
| 2022 Q2 | 2.28 Million EUR | 0.0% |
| 2022 FY | 1.93 Million EUR | -26.51% |
| 2021 Q4 | 2.63 Million EUR | 0.0% |
| 2021 FY | 2.63 Million EUR | -12.31% |
| 2021 Q2 | 3.01 Million EUR | 0.0% |
| 2020 Q2 | 634.56 Thousand EUR | 0.0% |
| 2020 FY | 3 Million EUR | 339.36% |
| 2020 Q4 | 3 Million EUR | 0.0% |
| 2019 Q2 | 733.12 Thousand EUR | 0.0% |
| 2019 Q4 | 684.08 Thousand EUR | 0.0% |
| 2019 FY | 684.08 Thousand EUR | 0.0% |
| 2018 FY | - EUR | -100.0% |
| 2018 Q2 | - EUR | 0.0% |
| 2018 Q4 | - EUR | 0.0% |
| 2017 Q2 | - EUR | 0.0% |
| 2017 FY | 1.84 Million EUR | 85.23% |
| 2017 Q4 | 1.84 Million EUR | 0.0% |
| 2016 Q2 | - EUR | 0.0% |
| 2016 Q4 | 998.52 Thousand EUR | 0.0% |
| 2016 FY | 998.52 Thousand EUR | 35.21% |
| 2015 FY | 738.52 Thousand EUR | 22.59% |
| 2015 Q4 | 738.52 Thousand EUR | 0.0% |
| 2015 Q2 | - EUR | 0.0% |
| 2014 FY | 602.45 Thousand EUR | 0.0% |
| 2014 Q4 | 602.45 Thousand EUR | 0.0% |
| 2013 FY | - EUR | 0.0% |
| 2012 FY | - EUR | 0.0% |
| 2011 FY | - EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | -12.708% |
| ABIVAX Société Anonyme | 44.69 Million EUR | 97.224% |
| Adocia SA | 4.54 Million EUR | 72.667% |
| Aelis Farma SA | 2.04 Million EUR | 39.409% |
| Biophytis S.A. | 3.11 Million EUR | 60.112% |
| Advicenne S.A. | 15.89 Million EUR | 92.194% |
| genOway Société anonyme | 5.51 Million EUR | 77.517% |
| IntegraGen SA | 642.28 Thousand EUR | -93.204% |
| Medesis Pharma S.A. | 1.2 Million EUR | -3.409% |
| Neovacs S.A. | 650 Thousand EUR | -90.909% |
| NFL Biosciences SA | 39.2 Thousand EUR | -3065.347% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 71.516% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | 36.699% |
| Theranexus Société Anonyme | 2.46 Million EUR | 49.571% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | 68.165% |
| TheraVet SA | 1 Million EUR | -24.017% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | 82.031% |
| argenx SE | 15.35 Million EUR | 91.918% |
| BioSenic S.A. | 15.57 Million EUR | 92.032% |
| Celyad Oncology SA | 902 Thousand EUR | -37.573% |
| DBV Technologies S.A. | 4.52 Million USD | 72.583% |
| Galapagos NV | 4.94 Million EUR | 74.901% |
| Genfit S.A. | 62.25 Million EUR | 98.007% |
| GeNeuro SA | 6.49 Million EUR | 80.886% |
| Hyloris Pharmaceuticals SA | 344 Thousand EUR | -260.73% |
| Innate Pharma S.A. | 30.6 Million EUR | 95.946% |
| Inventiva S.A. | 25.61 Million EUR | 95.156% |
| MaaT Pharma SA | 5.42 Million EUR | 77.126% |
| MedinCell S.A. | 52.8 Million EUR | 97.65% |
| Nanobiotix S.A. | 41.66 Million EUR | 97.021% |
| Onward Medical N.V. | 16.3 Million EUR | 92.39% |
| Oryzon Genomics S.A. | 3.45 Million EUR | 64.038% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | 96.505% |
| Oxurion NV | 117 Thousand EUR | -960.608% |
| Pharming Group N.V. | 123.65 Million EUR | 98.996% |
| Poxel S.A. | 40.14 Million EUR | 96.909% |
| GenSight Biologics S.A. | 1.04 Million EUR | -18.408% |
| Transgene SA | 17 Thousand EUR | -7199.476% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 2.87 Billion EUR | 99.957% |
| Valneva SE | 132.76 Million EUR | 99.065% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |